-
1
-
-
33744464516
-
A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia
-
Alvarez E., Ciudad A., Olivares J.M., Bousono M., and Gomez J.C. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J. Clin. Psychopharmacol. 26 3 (2006) 238-249
-
(2006)
J. Clin. Psychopharmacol.
, vol.26
, Issue.3
, pp. 238-249
-
-
Alvarez, E.1
Ciudad, A.2
Olivares, J.M.3
Bousono, M.4
Gomez, J.C.5
-
2
-
-
33750517755
-
Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form
-
Conley R., Gupta S.K., and Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr. Med. Res. Opin. 22 10 (2006) 1879-1892
-
(2006)
Curr. Med. Res. Opin.
, vol.22
, Issue.10
, pp. 1879-1892
-
-
Conley, R.1
Gupta, S.K.2
Sathyan, G.3
-
3
-
-
0030980659
-
The varied outcomes of schizophrenia
-
Davidson L., and McGlashan T.H. The varied outcomes of schizophrenia. Can. J. Psychiatry 42 1 (1997) 34-43
-
(1997)
Can. J. Psychiatry
, vol.42
, Issue.1
, pp. 34-43
-
-
Davidson, L.1
McGlashan, T.H.2
-
4
-
-
34249275309
-
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study
-
Davidson M., Emsley R., Kramer M., Ford L., Pan G., Lim P., and Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr. Res. 93 1-3 (2007) 117-130
-
(2007)
Schizophr. Res.
, vol.93
, Issue.1-3
, pp. 117-130
-
-
Davidson, M.1
Emsley, R.2
Kramer, M.3
Ford, L.4
Pan, G.5
Lim, P.6
Eerdekens, M.7
-
5
-
-
33646680982
-
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone
-
Gharabawi G.M., Lasser R.A., Bossie C.A., Zhu Y., and Amador X. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. Int. Clin. Psychopharmacol. 21 4 (2006) 233-240
-
(2006)
Int. Clin. Psychopharmacol.
, vol.21
, Issue.4
, pp. 233-240
-
-
Gharabawi, G.M.1
Lasser, R.A.2
Bossie, C.A.3
Zhu, Y.4
Amador, X.5
-
6
-
-
26444444254
-
Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy
-
Greenwood K.E., Landau S., and Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr. Bull. 31 4 (2005) 910-921
-
(2005)
Schizophr. Bull.
, vol.31
, Issue.4
, pp. 910-921
-
-
Greenwood, K.E.1
Landau, S.2
Wykes, T.3
-
7
-
-
0000238671
-
Clinical global impressions
-
Revised, 1976 edn, Rockville, Maryland: U.S. Department of Health and Human Services
-
Guy, W., 1976. 'Clinical global impressions', ECDEU Assessment Manual for Psychopharmacology (Revised, 1976 edn.; Rockville, Maryland: U.S. Department of Health and Human Services), 218-222.
-
(1976)
ECDEU Assessment Manual for Psychopharmacology
, pp. 218-222
-
-
Guy, W.1
-
9
-
-
67649851025
-
-
Invega, P.I. 2007. Janssen, L.P. Titusville, NJ.
-
Invega, P.I. 2007. Janssen, L.P. Titusville, NJ.
-
-
-
-
10
-
-
33846590147
-
Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial
-
Kane J., Canas F., Kramer M., Ford L., Gassmann-Mayer C., Lim P., and Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. 90 1-3 (2007) 147-161
-
(2007)
Schizophr. Res.
, vol.90
, Issue.1-3
, pp. 147-161
-
-
Kane, J.1
Canas, F.2
Kramer, M.3
Ford, L.4
Gassmann-Mayer, C.5
Lim, P.6
Eerdekens, M.7
-
11
-
-
0023606101
-
The positive and negative syndrome scale (PANSS) for schizophrenia
-
Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
-
(1987)
Schizophr. Bull.
, vol.13
, pp. 261-276
-
-
Kay, S.R.1
Fiszbein, A.2
Opler, L.A.3
-
12
-
-
33748743350
-
Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
-
Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., and Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 26 5 (2006) 453-461
-
(2006)
J. Clin. Psychopharmacol.
, vol.26
, Issue.5
, pp. 453-461
-
-
Kinon, B.J.1
Noordsy, D.L.2
Liu-Seifert, H.3
Gulliver, A.H.4
Ascher-Svanum, H.5
Kollack-Walker, S.6
-
13
-
-
0033952746
-
Assessing the efficacy of treatments for the deficit syndrome of schizophrenia
-
Kirkpatrick B., Kopelowicz A., Buchanan R.W., and Carpenter Jr. W.T. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 22 3 (2000) 303-310
-
(2000)
Neuropsychopharmacology
, vol.22
, Issue.3
, pp. 303-310
-
-
Kirkpatrick, B.1
Kopelowicz, A.2
Buchanan, R.W.3
Carpenter Jr., W.T.4
-
14
-
-
33645226430
-
The NIMH-MATRICS consensus statement on negative symptoms
-
Kirkpatrick B., Fenton W.S., Carpenter Jr. W.T., and Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32 2 (2006) 214-219
-
(2006)
Schizophr. Bull.
, vol.32
, Issue.2
, pp. 214-219
-
-
Kirkpatrick, B.1
Fenton, W.S.2
Carpenter Jr., W.T.3
Marder, S.R.4
-
15
-
-
33846235456
-
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study
-
Kramer M., Simpson G., Maciulis V., Kushner S., Vijapurkar U., Lim P., and Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 27 1 (2007) 6-14
-
(2007)
J. Clin. Psychopharmacol.
, vol.27
, Issue.1
, pp. 6-14
-
-
Kramer, M.1
Simpson, G.2
Maciulis, V.3
Kushner, S.4
Vijapurkar, U.5
Lim, P.6
Eerdekens, M.7
-
16
-
-
33749496746
-
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial
-
Lecrubier Y., Quintin P., Bouhassira M., Perrin E., and Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatry Scand. 114 5 (2006) 319-327
-
(2006)
Acta Psychiatry Scand.
, vol.114
, Issue.5
, pp. 319-327
-
-
Lecrubier, Y.1
Quintin, P.2
Bouhassira, M.3
Perrin, E.4
Lancrenon, S.5
-
17
-
-
33947713524
-
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia
-
Lindenmayer J.P., Khan A., Iskander A., Abad M.T., and Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J. Clin. Psychiatry 68 3 (2007) 368-379
-
(2007)
J. Clin. Psychiatry
, vol.68
, Issue.3
, pp. 368-379
-
-
Lindenmayer, J.P.1
Khan, A.2
Iskander, A.3
Abad, M.T.4
Parker, B.5
-
18
-
-
0031431410
-
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials
-
Marder S.R., Davis J.M., and Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 58 12 (1997) 538-546
-
(1997)
J. Clin. Psychiatry
, vol.58
, Issue.12
, pp. 538-546
-
-
Marder, S.R.1
Davis, J.M.2
Chouinard, G.3
-
19
-
-
36048941530
-
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study
-
Marder S.R., Kramer M., Ford L., Eerdekens E., Lim P., Eerdekens M., and Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol. Psychiatry 62 12 (2007) 1363-1370
-
(2007)
Biol. Psychiatry
, vol.62
, Issue.12
, pp. 1363-1370
-
-
Marder, S.R.1
Kramer, M.2
Ford, L.3
Eerdekens, E.4
Lim, P.5
Eerdekens, M.6
Lowy, A.7
-
20
-
-
45249095185
-
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies
-
Meltzer H.Y., Bobo W.V., Nuamah I.F., Lane R., Hough D., Kramer M., and Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J. Clin. Psychiatry 60 5 (2008) 817-829
-
(2008)
J. Clin. Psychiatry
, vol.60
, Issue.5
, pp. 817-829
-
-
Meltzer, H.Y.1
Bobo, W.V.2
Nuamah, I.F.3
Lane, R.4
Hough, D.5
Kramer, M.6
Eerdekens, M.7
-
21
-
-
14844321950
-
Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up
-
Milev P., Ho B.C., Arndt S., and Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 162 3 (2005) 495-506
-
(2005)
Am. J. Psychiatry
, vol.162
, Issue.3
, pp. 495-506
-
-
Milev, P.1
Ho, B.C.2
Arndt, S.3
Andreasen, N.C.4
-
22
-
-
0035676596
-
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia
-
Moller H.J. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 251 5 (2001) 217-224
-
(2001)
Eur. Arch. Psychiatry Clin. Neurosci.
, vol.251
, Issue.5
, pp. 217-224
-
-
Moller, H.J.1
-
23
-
-
0028946201
-
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study
-
Moller H.J., Muller H., Borison R.L., Schooler N.R., and Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. 245 1 (1995) 45-49
-
(1995)
Eur. Arch. Psychiatry Clin. Neurosci.
, vol.245
, Issue.1
, pp. 45-49
-
-
Moller, H.J.1
Muller, H.2
Borison, R.L.3
Schooler, N.R.4
Chouinard, G.5
-
24
-
-
0034022621
-
Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning
-
Morosini P.L., Magliano L., Brambilla L., Ugolini S., and Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatry Scand. 101 4 (2000) 323-329
-
(2000)
Acta Psychiatry Scand.
, vol.101
, Issue.4
, pp. 323-329
-
-
Morosini, P.L.1
Magliano, L.2
Brambilla, L.3
Ugolini, S.4
Pioli, R.5
-
25
-
-
54049089510
-
Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia
-
Nasrallah H., Morosini P., and Gagnon D.D. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 161 2 (2008) 213-224
-
(2008)
Psychiatry Res.
, vol.161
, Issue.2
, pp. 213-224
-
-
Nasrallah, H.1
Morosini, P.2
Gagnon, D.D.3
-
26
-
-
33646698646
-
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study
-
Olie J.P., Spina E., Murray S., and Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int. Clin. Psychopharmacol. 21 3 (2006) 143-151
-
(2006)
Int. Clin. Psychopharmacol.
, vol.21
, Issue.3
, pp. 143-151
-
-
Olie, J.P.1
Spina, E.2
Murray, S.3
Yang, R.4
-
27
-
-
64249129738
-
Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia
-
Patrick D.L., Burns T., Morosini P., Rothman M., Gagnon D.D., Wild D., and Adriaenssen I. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr. Med. Res. Opin. 25 2 (2009) 325-338
-
(2009)
Curr. Med. Res. Opin.
, vol.25
, Issue.2
, pp. 325-338
-
-
Patrick, D.L.1
Burns, T.2
Morosini, P.3
Rothman, M.4
Gagnon, D.D.5
Wild, D.6
Adriaenssen, I.7
-
28
-
-
0038826191
-
Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia
-
Pickar D., and Bartko J.J. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. Am. J. Psychiatry 160 6 (2003) 1133-1138
-
(2003)
Am. J. Psychiatry
, vol.160
, Issue.6
, pp. 1133-1138
-
-
Pickar, D.1
Bartko, J.J.2
-
29
-
-
29744458402
-
Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms
-
Riedel M., Muller N., Strassnig M., Spellmann I., Engel R.R., Musil R., Dehning S., Douhet A., Schwarz M.J., and Moller H.J. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 255 6 (2005) 432-437
-
(2005)
Eur. Arch. Psychiatry Clin. Neurosci.
, vol.255
, Issue.6
, pp. 432-437
-
-
Riedel, M.1
Muller, N.2
Strassnig, M.3
Spellmann, I.4
Engel, R.R.5
Musil, R.6
Dehning, S.7
Douhet, A.8
Schwarz, M.J.9
Moller, H.J.10
-
30
-
-
34249329193
-
Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms
-
Ruhrmann S., Kissling W., Lesch O.M., Schmauss M., Seemann U., and Philipp M. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 5 (2007) 1012-1022
-
(2007)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.31
, Issue.5
, pp. 1012-1022
-
-
Ruhrmann, S.1
Kissling, W.2
Lesch, O.M.3
Schmauss, M.4
Seemann, U.5
Philipp, M.6
-
32
-
-
11144311888
-
Quetiapine has a direct effect on the negative symptoms of schizophrenia
-
Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum. Psychopharmacol. 19 8 (2004) 559-563
-
(2004)
Hum. Psychopharmacol.
, vol.19
, Issue.8
, pp. 559-563
-
-
Tandon, R.1
-
33
-
-
0031003781
-
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
-
Tollefson G.D., and Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry 154 4 (1997) 466-474
-
(1997)
Am. J. Psychiatry
, vol.154
, Issue.4
, pp. 466-474
-
-
Tollefson, G.D.1
Sanger, T.M.2
-
34
-
-
56849096505
-
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
-
Turkoz I., Bossie C.A., Dirks B., and Canuso C.M. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr. Dis. Treat. 4 5 (2008) 949-958
-
(2008)
Neuropsychiatr. Dis. Treat.
, vol.4
, Issue.5
, pp. 949-958
-
-
Turkoz, I.1
Bossie, C.A.2
Dirks, B.3
Canuso, C.M.4
|